Amneal Pharmaceuticals, Inc. (AMRX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Bridgewater, NJ, United States. Der aktuelle CEO ist Chirag K. Patel.
AMRX hat IPO-Datum 2018-05-07, 8,300 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $4.13B.
Amneal Pharmaceuticals, Inc. is a diversified pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products across multiple dosage forms and therapeutic areas. The company operates through three segments: Generics, which produces complex oral solids, injectables, ophthalmics, and other formulations; Specialty, which markets branded products for central nervous system disorders, endocrinology, and parasitic infections including brands like Rytary and Unithroid; and AvKARE, which supplies pharmaceuticals and medical products to government agencies and the Department of Defense. Amneal serves customers through wholesalers, distributors, hospitals, and retail pharmacies across the United States, India, Ireland, and internationally. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company has established itself as a significant player in both the generic and specialty pharmaceutical markets.
